Fulgent Genetics Stock Plunges 40% After Q4 2025 Earnings Report

Analyst sees major market misconception about the company's future prospects.

Mar. 12, 2026 at 1:11pm

Got story updates? Submit your updates here. ›

Fulgent Genetics, a genetic testing company, saw its stock price decline by nearly 40% after releasing its Q4 2025 earnings report. The report announced the upcoming departure of the company's single largest customer, which was seen as a major setback by investors. A value investor and Seeking Alpha contributor analyzes the situation and argues that the market has misunderstood Fulgent Genetics' long-term prospects.

Why it matters

Fulgent Genetics is a prominent player in the genetic testing industry, and its stock performance is closely watched by investors. The significant stock price decline following the earnings report suggests that the market may have overreacted to the news of the customer departure, potentially creating an opportunity for value-oriented investors.

The details

According to the Seeking Alpha article, Fulgent Genetics' Q4 2025 earnings report revealed the upcoming departure of the company's single largest customer. This news was seen as a major setback by investors, leading to a nearly 40% single-day decline in the stock price. The author, a value investor, argues that the market has misunderstood the long-term prospects of Fulgent Genetics, and that the company's fundamentals remain strong.

  • Fulgent Genetics released its Q4 2025 earnings report on March 12, 2026.

The players

Fulgent Genetics

A genetic testing company that provides a range of genetic testing services to customers.

Frederick Wittmann

A value investor and Seeking Alpha contributor who focuses on deep value plays in the technology sector.

Got photos? Submit your photos here. ›

What they’re saying

“I am a value investor with a concentrated portfolio, focusing on rare and exceptional buying opportunities. As a keen reader of Value Investing literature, I am well versed in the teachings of 'super investors' such as Warren Buffett, Charlie Munger, Benjamin Graham and several others.”

— Frederick Wittmann, Value Investor and Seeking Alpha Contributor (Seeking Alpha)

The takeaway

This case highlights the importance of understanding a company's fundamentals beyond a single earnings report or news event. The market's overreaction to Fulgent Genetics' customer departure announcement may present a buying opportunity for value-oriented investors who can see past the short-term noise and focus on the company's long-term prospects.